TipRanksStock Market NewsABMD NewsBTIG Reaffirms Their Hold Rating on Abiomed (ABMD)

BTIG Reaffirms Their Hold Rating on Abiomed (ABMD)

BTIG analyst Marie Thibault maintained a Hold rating on Abiomed (ABMDResearch Report) today. The company’s shares closed last Thursday at $289.12.

According to TipRanks.com, Thibault is a 5-star analyst with an average return of 23.2% and a 34.3% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Edwards Lifesciences.

The word on The Street in general, suggests a Hold analyst consensus rating for Abiomed with a $375.67 average price target.

See today’s best-performing stocks on TipRanks >>

Abiomed’s market cap is currently $14.01B and has a P/E ratio of 94.72.

Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABMD in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded in 1981 and is headquartered in Danvers, MA.

Read More on ABMD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More